Jupiter Neurosciences, Inc. Share Price
NASDAQ: JUNS | Micro CapJupiter Neurosciences, Inc. Stock Performance
Open $5.20 | Prev. Close $5.15 | Circuit Range N/A |
Day Range $5.04 - $5.20 | Year Range $0.07 - $5.20 | Volume 794 |
Average Traded $5.15 |
Jupiter Neurosciences, Inc. Share Price Today
As of 10 August 2026, Jupiter Neurosciences, Inc.'s share price is $5.25. The stock opened at $5.20, compared to its previous close of $5.15. During today's trading session, Jupiter Neurosciences, Inc.'s share price traded between $5.04 and $5.20, with an average price of $5.12. Over the past 52 weeks, the stock has recorded a high of $5.20 and a low of $0.07. In terms of performance, Jupiter Neurosciences, Inc.'s share price has risen by 875.84% over the last six months and is up 254.73% on a year-on-year basis.
Jupiter Neurosciences, Inc. Share Price Chart
Jupiter Neurosciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $181.80M | PE Ratio (TTM) -21.00 | Dividend Yield N/A |
EPS (TTM) $-0.25 | Revenue (TTM) $21796.00 | Return On Equity (TTM) 471.92% |
Profit Margin -39662.77% | Debt to Equity -4.04 | Quarterly Earnings Growth YoY -287.13% |
Jupiter Neurosciences, Inc. Quarterly Profit & Loss
All figures in USD
Jupiter Neurosciences, Inc. Annual Profit & Loss
All figures in USD
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Jupiter Neurosciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.10 | $5.15 | +5,559.34% |
Jul 2026 | $0.21 | $0.09 | -57.67% |
Jun 2026 | $0.25 | $0.21 | -17.31% |
May 2026 | $0.39 | $0.26 | -32.99% |
Apr 2026 | $0.37 | $0.39 | +20.50% |
Mar 2026 | $0.49 | $0.32 | -40.15% |
Feb 2026 | $0.57 | $0.54 | +6.11% |
Jan 2026 | $1.00 | $0.51 | -53.06% |
Dec 2025 | $1.21 | $1.08 | -12.20% |
Nov 2025 | $1.38 | $1.23 | -11.51% |
Oct 2025 | $1.71 | $1.39 | -19.65% |
Sep 2025 | $1.42 | $1.73 | +16.89% |
JUNS Share Price FAQs
What is Jupiter Neurosciences, Inc. share price today?
What is the 52 week high and 52 week low of Jupiter Neurosciences, Inc. stock?
What is JUNS's market capitalisation today?
What is JUNS's net income for the last quarter?
What is the 5 year returns of JUNS?
What is the high & low stock price of JUNS today?
Can I buy JUNS shares in India?